Besides, the killing advantage of miR155 co-expressing anti-CD19 CAR-T cells to hCD19-SW620 cells showed its potential of application on solid tumors, not just on blood tumors. This evidence concerns the gene CD19 and hematopoietic and lymphoid system neoplasm.